varespladib has been researched along with Apoplexy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kastelein, JJP; Lincoff, AM; Mani, P; Menon, V; Nicholls, SJ; Nissen, SE; Puri, R; Schwartz, GG; Shao, M | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
2 trial(s) available for varespladib and Apoplexy
| Article | Year |
|---|---|
Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Australia; C-Reactive Protein; Death; Europe; Female; Humans; India; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; New Zealand; North America; Phospholipase A2 Inhibitors; Placebos; Risk Factors; Stroke; Treatment Outcome | 2019 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |